Press release
Opioid Receptor Agonist Pipeline Analysis, 2022 | Insights Into the Clinical & Non-Clinical Activities, Commercial Developments, Regulatory Approvals, and Key Companies Active in the Market
Opioid Receptor Agonist Pipeline
"Opioid Receptor Agonist Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Opioid Receptor Agonist Therapeutics Market.
The report provides a detailed description of the pipeline drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Opioid Receptor Agonist Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Opioid Receptor Agonist drugs.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development in the Opioid Receptor Agonist segment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements, and financing details in the Opioid Receptor Agonist market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Delveinsight's Report Covers 40+ Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/opioid-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Opioid Receptor Agonist Therapeutics Assessment
There are approx. 40+ key companies are developing therapies for Opioid Receptor Agonists. Currently, Acura Pharmaceuticals has its Opioid Receptor Agonists drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Opioid Receptor Agonist Market Landscape Include:
• Trevena
• Titan Pharmaceuticals
• Lumosa Therapeutics
• Astraea Therapeutics
• Alar Pharmaceuticals
• Ensysce Biosciences
And many more
Opioid Receptor Agonist Pipeline Products Covered in the Report Include
• LTX-03: Acura Pharmaceuticals
TRV-734: Trevena
And many others
Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/opioid-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Introduction
2. Executive Summary
3. Opioid Receptor Agonist: In-depth Overview
4. Pipeline Therapeutics & Comparative Analysis
5. Therapeutic Assessment
6. Opioid Receptor Agonist - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment (Collaborations, Licensing/Partnering, Acquisition -Deal Value Trends)
8. Late-Stage Products (Phase III)
9. Mid-Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Pre-clinical and Discovery Stage Products
12. Inactive Products
13. Opioid Receptor Agonist Key Companies
14. Opioid Receptor Agonist Key Products
15. Opioid Receptor Agonist Unmet Needs
16. Opioid Receptor Agonist - Market Drivers and Barriers
17. Opioid Receptor Agonist Future Perspectives and Conclusion
18. Opioid Receptor Agonist Analyst Views
19. Appendix
*The table of contents is not exhaustive; the final content may vary.
Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/opioid-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/opioid-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Opioid Receptor Agonist Pipeline Analysis, 2022 | Insights Into the Clinical & Non-Clinical Activities, Commercial Developments, Regulatory Approvals, and Key Companies Active in the Market here
News-ID: 2822143 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Opioid
Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Opioid-Induced Constipation Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for treatment of opioid-induced constipation has seen a substantial growth recently. It is expected to escalate from a solid $1.78 billion in 2024 to an impressive $1.9 billion in 2025, exhibiting…
Growing Number Of Opioid Addiction Cases: Strategic Insights Driving Opioid Use …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Opioid Use Disorder (OUD) Market Size By 2025?
The market size for opioid use disorder (OUD) has experienced a quick expansion in the past few years. The growth is projected to rise from $3.96 billion in 2024 to $4.39 billion in 2025, boasting a compound…
Key Influencer in the Opioid-Induced Constipation Treatment Market 2025: Rising …
What combination of drivers is leading to accelerated growth in the opioid-induced constipation treatment market?
The rise in opioid administration for cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market. Opioids are commonly used for managing moderate to severe pain, but they can cause constipation. OIC treatments are vital for improving the quality of life for patients on opioids, allowing them to maintain…
Top Factor Driving Opioid Use Disorder (OUD) Market Growth in 2025: Growing Numb …
How Are the key drivers contributing to the expansion of the opioid use disorder (oud) market?
The rise in instances of opioid dependency is set to fuel the expansion of the opioid use disorder (OUD) market. Opioid dependency defines a health concern marked by habitual and uncontrolled opioid consumption which negatively impacts health. These opioids can generate feelings of bliss and relief from pain, but continued usage often results in tolerance…
What's Driving the Opioid-Induced Constipation Treatment Market 2025-2034: Risin …
What Are the Projections for the Size and Growth Rate of the Opioid-Induced Constipation Treatment Market?
The market size for treatments of constipation caused by opioids has seen robust growth lately. The forecasted growth indicates an increase from $1.78 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This past growth is associated with a growing elderly population, individualized treatments for OIC, the…
MEDICAL MARIJUANA AND THE OPIOID CRISIS
Marijuana from the Cannabis plant is classified as a psychoactive drug used for medical or recreational purposes. Although it has been used for decades, in the U.S., it is still illegal under federal law to use and possess marijuana.
Get PDF Sample Brochure of this report at: https://decisionmarketreports.com/request-sample/1247622
Nevertheless, at the state level, policies regarding the medical and recreational use of Cannabis vary greatly, and in many states conflict significantly with federal…
